Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09SUO
|
|||
| Former ID |
DIB020977
|
|||
| Drug Name |
splitomicin
|
|||
| Synonyms |
splitomicin; 5690-03-9; 1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C13H10O2
|
|||
| Canonical SMILES |
C1CC(=O)OC2=C1C3=CC=CC=C3C=C2
|
|||
| InChI |
1S/C13H10O2/c14-13-8-6-11-10-4-2-1-3-9(10)5-7-12(11)15-13/h1-5,7H,6,8H2
|
|||
| InChIKey |
ISFPDBUKMJDAJH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 5690-03-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5614465, 8153240, 11114129, 11121743, 11122223, 11362870, 11365432, 11367994, 11370951, 11370952, 11373595, 11376156, 12015614, 15487777, 24724608, 26752214, 26759555, 29224324, 47662436, 47810888, 50104892, 57322688, 74857037, 81055019, 85788291, 91722326, 92310094, 99301006, 99302526, 99375476, 103092662, 103148024, 103297410, 104308751, 117601689, 121363829, 125333607, 132570953, 134964522, 137468463, 160657168, 162023121, 162248340, 163687300, 163835543, 172089098, 175608088, 176236732, 184021964, 223366898
|
|||
| ChEBI ID |
CHEBI:75272
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NAD-dependent deacetylase sirtuin-1 (SIRT1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | FoxO signaling pathway | |||
| AMPK signaling pathway | ||||
| Glucagon signaling pathway | ||||
| Amphetamine addiction | ||||
| MicroRNAs in cancer | ||||
| Panther Pathway | p53 pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| Signaling events mediated by HDAC Class III | ||||
| E2F transcription factor network | ||||
| HIF-2-alpha transcription factor network | ||||
| Signaling events mediated by HDAC Class I | ||||
| FoxO family signaling | ||||
| Regulation of Androgen receptor activity | ||||
| Regulation of retinoblastoma protein | ||||
| Reactome | RORA activates gene expression | |||
| Regulation of HSF1-mediated heat shock response | ||||
| Circadian Clock | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15113-8. | |||
| REF 2 | Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specif... J Med Chem. 2010 Feb 11;53(3):1407-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.